ADIL

Adial Pharmaceuticals, Inc.

Price Chart

Latest Quote

$2.21

-0.21 (-8.68%)

Current Price

Previous Close	$2.42
Open	$2.38
Day High	$2.38
Day Low	$2.20
Volume	47,001

Fetched: 2026-06-06T03:42:09

Stock Information

Shares Outstanding	2.14M
Cash Equivalents	$4.58M
Net Income	$-7.77M
Sector	Healthcare
Industry	Biotechnology
Market Cap	$4.74M
EPS (TTM)	$-4.89
Exchange	NCM

🌐 Visit Website

📊 Comprehensive Analysis

Company Data

Enterprise Value	$153K
Income	$-7.77M
Book/sh	$2.46
Cash/sh	$2.14
Employees	5

Financial Ratios

Quick Ratio	3.04
Current Ratio	3.18

Returns & Margins

ROA	-110.91%
ROE	-265.94%

Ownership

Insider Ownership	5.32%
Institutional Ownership	14.45%
Insider & Institutional transactions data not available

Valuation Ratios

Forward P/E	-0.89
P/B	0.90

Analyst Data

Recommendation	none
Target Price	$25.00

Technical Indicators

SMA20	$2.00
SMA50	$1.77
SMA200	$5.37
RSI	67.97
ATR	0.2750

Shares Float	1.93M
Short Float	2.39%
Short Ratio	0.51
Rel Volume	0.25

Performance History

Week	-7.92%
Month	+39.87%
Quarter	+20.77%
6 Months	-72.37%
YTD	-63.17%
Year	-86.81%
3 Years	-98.64%
5 Years	-99.86%
10 Years	-99.91%

Stock Score: ⭐ Premium

Based on debt, profitability, growth, and cash flow metrics

⭐ Premium Feature

Recent Price History

Date	Close	Volume
2026-06-05	$2.21	47,001
2026-06-04	$2.42	28,600
2026-06-03	$2.32	21,200
2026-06-02	$2.36	22,100
2026-06-01	$2.45	42,500
2026-05-29	$2.40	42,700
2026-05-28	$2.53	89,600
2026-05-27	$2.39	87,100
2026-05-26	$2.24	177,500
2026-05-22	$2.08	143,600
2026-05-21	$2.30	172,500
2026-05-20	$2.35	332,700
2026-05-19	$2.06	1,778,200
2026-05-18	$1.61	355,700
2026-05-15	$1.38	81,300
2026-05-14	$1.36	69,100
2026-05-13	$1.38	55,600
2026-05-12	$1.38	45,300
2026-05-11	$1.44	82,100
2026-05-08	$1.43	122,800
2026-05-07	$1.42	203,000
2026-05-06	$1.58	140,700

About Adial Pharmaceuticals, Inc.

Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. The company's lead product is AD04, a serotonin-3 antagonist, which is in Phase 3 clinical trials for the treatment of alcohol use disorder. It is also involved in the development of drug candidates for non-opioid pain reduction and other diseases and disorders. The company was founded in 2010 and is based in Glen Allen, Virginia.

📰 Latest News

Has Acurx Pharmaceuticals (ACXP) Outpaced Other Medical Stocks This Year?

Zacks • 2026-01-06T14:40:03Z

CoreWeave initiated, Instacart downgraded: Wall Street's top analyst calls

The Fly • 2025-09-30T13:42:24Z

Adial Pharmaceuticals Highlights Favorable Comments From FDA Meeting For Lead Program In Alcohol Use Disorder

Benzinga • 2025-09-16T12:03:43Z

All You Need to Know About Adial Pharmaceuticals (ADIL) Rating Upgrade to Buy

Zacks • 2025-09-01T16:00:02Z

Thermo Fisher Scientific (TMO) Inks Deal to Manufacture Adial Pharmaceuticals ADO4

Insider Monkey • 2025-07-15T13:10:38Z

Adial Pharmaceuticals (ADIL) Upgraded to Strong Buy: Here's Why

Zacks • 2025-07-10T16:00:03Z

Top Midday Decliners

MT Newswires • 2025-06-17T18:50:19Z

EXCLUSIVE: Adial Pharmaceuticals Lead Candidate For Alcohol Use Disorder Advances Toward Phase 3 Trial

Benzinga • 2025-06-11T11:30:44Z

Period:

Income Statement (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Revenue
Total Revenue	$0	$0	$0	$0
Operating Revenue	$0	$0	$0	$0
Expenses
Total Expenses	$7,799,462	$8,284,457	$6,887,947	$10,859,475
Other Income Expense	$-327,276	$-5,091,653	$-183,722	$522,000
Other Non Operating Income Expenses	$164,854	$-75,043	$10,162	-
Net Non Operating Interest Income Expense	$149,567	$178,659	$69,779	$63,338
Operating Expense	$7,799,462	$8,284,457	$6,887,947	$10,859,475
General And Administrative Expense	$5,179,791	$5,055,231	$5,620,870	$8,909,167
Income & Earnings
Net Income From Continuing Operation Net Minority Interest	$-7,977,171	$-13,197,451	$-7,001,890	$-10,796,137
Net Interest Income	$149,567	$178,659	$69,779	$63,338
Interest Income	$149,567	$178,659	$69,779	$63,338
Normalized Income	$-7,977,171	$-8,733,024	$-7,001,890	$-10,796,137
Net Income From Continuing And Discontinued Operation	$-7,977,171	$-13,197,451	$-5,123,341	$-12,731,416
Total Operating Income As Reported	$-7,799,462	$-8,284,457	$-6,887,947	$-10,859,475
Net Income Common Stockholders	$-7,977,171	$-13,197,451	$-5,123,341	$-12,731,416
Net Income	$-7,977,171	$-13,197,451	$-5,123,341	$-12,731,416
Net Income Including Noncontrolling Interests	$-7,977,171	$-13,197,451	$-5,123,341	$-12,731,416
Net Income Continuous Operations	$-7,977,171	$-13,197,451	$-7,001,890	$-10,796,137
Pretax Income	$-7,977,171	$-13,197,451	$-7,001,890	$-10,796,137
Special Income Charges	$0	$-4,464,427	$0	$522,000
Earnings From Equity Interest	$-492,130	$-552,183	$-193,884	$0
Interest Income Non Operating	$149,567	$178,659	$69,779	$63,338
Operating Income	$-7,799,462	$-8,284,457	$-6,887,947	$-10,859,475
Net Income Discontinuous Operations	-	$0	$1,878,549	$-1,935,279
Per Share
Diluted EPS	$-11.93	$-68.01	$-90.00	$-317.75
Basic EPS	$-11.93	$-68.01	$-90.00	$-317.75
Other
Tax Effect Of Unusual Items	$0	$0	$0	$0
Tax Rate For Calcs	$0	$0	$0	$0
Normalized EBITDA (Bullshit earnings)	$-7,798,897	$-3,819,465	$-6,887,383	$-10,858,911
Total Unusual Items	$0	$-4,464,427	$0	$522,000
Total Unusual Items Excluding Goodwill	$0	$-4,464,427	$0	$522,000
Reconciled Depreciation	$565	$565	$564	$564
EBITDA (Bullshit earnings)	$-7,798,897	$-8,283,892	$-6,887,383	$-10,858,911
EBIT	$-7,799,462	$-8,284,457	$-6,887,947	$-10,859,475
Diluted Average Shares	$668,630	$194,059	$56,986	$40,060
Basic Average Shares	$668,630	$194,059	$56,986	$40,060
Diluted NI Availto Com Stockholders	$-7,977,171	$-13,197,451	$-5,123,341	$-12,731,416
Research And Development	$2,619,671	$3,229,226	$1,267,077	$1,950,308
Selling General And Administration	$5,179,791	$5,055,231	$5,620,870	$8,909,167
Other Gand A	$5,179,791	$5,055,231	$5,620,870	$8,909,167
Tax Provision	-	$0	$0	$0
Other Special Charges	-	$4,464,427	-	-
Write Off	-	-	-	$0
Restructuring And Mergern Acquisition	-	-	-	$-522,000
Impairment Of Capital Assets	-	-	-	-

Fetched: 2026-06-02

Balance Sheet (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Assets
Net Tangible Assets	$5,273,674	$4,064,736	$4,079,616	$3,272,017
Total Assets	$6,673,367	$5,043,942	$4,736,605	$5,732,804
Total Non Current Assets	$492,484	$985,178	$1,537,926	$952,869
Goodwill And Other Intangible Assets	$2,784	$3,348	$3,913	$4,477
Current Assets	$6,180,883	$4,058,764	$3,198,679	$4,779,935
Other Current Assets	$299,666	$308,239	$371,597	$349,441
Cash Cash Equivalents And Short Term Investments	$5,881,217	$3,750,525	$2,827,082	$4,001,794
Cash And Cash Equivalents	$5,881,217	$3,750,525	$2,827,082	$4,001,794
Other Intangible Assets	-	-	$3,913	$4,477
Assets Held For Sale Current	-	-	$0	$428,700
Other Non Current Assets	-	-	-	$948,392
Prepaid Assets	-	-	-	$428,700
Non Current Prepaid Assets	-	-	-	-
Debt
Total Debt	-	-	-	$207,375
Long Term Debt And Capital Lease Obligation	-	-	-	$150,547
Current Debt And Capital Lease Obligation	-	-	-	$56,828
Liabilities
Total Liabilities Net Minority Interest	$1,396,909	$975,858	$653,076	$2,456,310
Total Non Current Liabilities Net Minority Interest	$0	$0	$0	$665,444
Current Liabilities	$1,396,909	$975,858	$653,076	$1,790,866
Payables And Accrued Expenses	$736,602	$570,612	$231,711	$653,228
Payables	$655,207	$298,402	$127,387	$276,410
Accounts Payable	$655,207	$250,130	$103,325	$276,410
Liabilities Heldfor Sale Non Current	-	-	$0	$665,444
Other Non Current Liabilities	-	-	-	$492,000
Non Current Deferred Liabilities	-	-	-	$22,897
Non Current Deferred Taxes Liabilities	-	-	-	$22,897
Other Current Liabilities	-	-	-	$376,129
Equity
Common Stock Equity	$5,276,458	$4,068,084	$4,083,529	$3,276,494
Total Equity Gross Minority Interest	$5,276,458	$4,068,084	$4,083,529	$3,276,494
Stockholders Equity	$5,276,458	$4,068,084	$4,083,529	$3,276,494
Retained Earnings	$-89,972,494	$-81,995,323	$-68,797,872	$-63,674,531
Long Term Equity Investment	$489,700	$981,830	$1,534,013	$0
Other
Ordinary Shares Number	$1,111,010	$258,983	$66,536	$42,699
Share Issued	$1,111,010	$258,983	$66,536	$42,699
Tangible Book Value	$5,273,674	$4,064,736	$4,079,616	$3,272,017
Invested Capital	$5,276,458	$4,068,084	$4,083,529	$3,276,494
Working Capital	$4,783,974	$3,082,906	$2,545,603	$2,989,069
Total Capitalization	$5,276,458	$4,068,084	$4,083,529	$3,276,494
Additional Paid In Capital	$95,247,841	$86,063,148	$72,879,738	$66,949,958
Capital Stock	$1,111	$259	$1,663	$1,067
Common Stock	$1,111	$259	$1,663	$1,067
Preferred Stock	$0	$0	$0	$0
Pensionand Other Post Retirement Benefit Plans Current	$660,307	$405,246	$421,365	$761,509
Current Accrued Expenses	$81,395	$272,210	$104,324	$376,818
Dueto Related Parties Current	$0	$48,272	$24,062	$0
Investments And Advances	$489,700	$981,830	$1,534,013	$0
Treasury Shares Number	-	-	$0	-
Capital Lease Obligations	-	-	-	$207,375
Long Term Capital Lease Obligation	-	-	-	$150,547
Current Capital Lease Obligation	-	-	-	$56,828
Goodwill	-	-	-	$248,971
Net PPE	-	-	-	$244,421
Gross PPE	-	-	-	$244,421
Other Properties	-	-	-	$50,424
Buildings And Improvements	-	-	-	$193,997
Properties	-	-	-	$0

Fetched: 2026-06-02

Cash Flow Statement (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Free Cash Flow
Free Cash Flow	$-6,492,603	$-6,922,306	$-6,806,809	$-11,185,985
Operating Activities
Operating Cash Flow	$-6,492,603	$-6,922,306	$-6,806,809	$-11,185,985
Cash Flow From Continuing Operating Activities	$-6,492,603	$-6,922,306	$-5,803,368	$-8,593,866
Operating Gains Losses	$492,130	$552,183	$193,884	-
Cash From Discontinued Operating Activities	-	-	$-1,003,441	$-2,592,119
Investing Activities
Investing Cash Flow	$150,000	$0	$1,500,000	$0
Cash Flow From Continuing Investing Activities	$150,000	$0	$1,500,000	$0
Net Other Investing Changes	-	-	$1,500,000	-
Capital Expenditure	-	-	-	-
Financing Activities
Issuance Of Capital Stock	$3,658,552	$4,021,485	$749,943	$9,123,741
Financing Cash Flow	$8,473,295	$7,845,749	$4,132,097	$9,125,606
Cash Flow From Continuing Financing Activities	$8,473,295	$7,845,749	$4,132,097	$9,125,606
Net Common Stock Issuance	$3,658,552	$4,021,485	$749,943	$9,123,741
Common Stock Issuance	$3,658,552	$4,021,485	$749,943	$9,123,741
Net Other Financing Charges	-	-	$-1,661	-
Other
End Cash Position	$5,881,217	$3,750,525	$2,827,082	$4,001,794
Beginning Cash Position	$3,750,525	$2,827,082	$4,001,794	$6,062,173
Changes In Cash	$2,130,692	$923,443	$-1,174,712	$-2,060,379
Proceeds From Stock Option Exercised	$4,814,743	$3,824,264	$3,383,815	$1,865
Net Business Purchase And Sale	$150,000	$0	-	$0
Sale Of Business	$150,000	$0	-	$0
Change In Working Capital	$465,673	$386,140	$-794,205	$-1,172,786
Change In Payables And Accrued Expense	$457,101	$322,782	$-772,049	$-1,222,777
Change In Accrued Expense	$100,296	$151,767	$-612,638	$-1,238,603
Change In Payable	$356,805	$171,015	$-159,411	$15,826
Change In Account Payable	$356,805	$171,015	$-159,411	$15,826
Change In Prepaid Assets	$8,572	$63,358	$-22,156	$49,991
Other Non Cash Items	$-150,000	$4,539,426	$51,901	$-522,000
Stock Based Compensation	$676,200	$796,831	$1,746,378	$3,374,493
Depreciation Amortization Depletion	$565	$565	$564	$564
Depreciation And Amortization	$565	$565	$564	$564
Amortization Cash Flow	$565	$565	$564	$564
Amortization Of Intangibles	$565	$565	$564	$564
Earnings Losses From Equity Investments	$492,130	$552,183	$193,884	$0
Net Income From Continuing Operations	$-7,977,171	$-13,197,451	$-7,001,890	$-10,796,137
Interest Paid Supplemental Data	-	$0	$0	$0
Income Tax Paid Supplemental Data	-	$0	$0	$0
Net PPE Purchase And Sale	-	-	-	$0
Purchase Of PPE	-	-	-	$0
Change In Other Current Liabilities	-	-	-	$-49,585
Asset Impairment Charge	-	-	-	$0
Deferred Tax	-	-	-	$-502
Deferred Income Tax	-	-	-	$-502
Depreciation	-	-	-	$59,937
Gain Loss On Sale Of PPE	-	-	-	$0

Fetched: 2026-06-02